论文部分内容阅读
据一项新发表的研究,溶血栓剂Eminase(甲氧苯酞酸纤维蛋白溶酶原链激酶激活剂复合物,简称APSAC)与安慰剂相比,减少一半心肿病发作病人的死亡率。此复合物的商品名为Eminase。多中心研究包括1004名病人。用安慰剂治疗的近13％病人在30天内死亡,用Eminase治疗的502名病人中,只有6.4％死亡。由于以前报道用药后死亡率差别很大,负责人认为应用安慰剂治疗病人不道德,故此项研究在早期已停止。
According to a newly published study, hemolysis suppository Eminase (trimetophenone plasminogen streptokinase activator complex, referred to as APSAC) compared with placebo, reduce the incidence of heart failure in patients with mortality. The complex is marketed as Eminase. The multicenter study included 1004 patients. Nearly 13% of patients treated with placebo died within 30 days and only 6.4% of 502 patients treated with Eminase died. Due to the large differences in mortality rates previously reported, the study concluded that the study stopped using the placebo for the treatment of patients.